secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001564590-22-023734
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma appoints Jacob Ma-Weaver, from largest shareholder, to board; explores strategic alternatives
--------------------------------------------------------------------------------

- Jacob Ma-Weaver appointed as Class III director effective June 15, 2022, term through 2024 annual meeting.
- Ma-Weaver is managing member of Cable Car Capital, ARCA's largest shareholder.
- Cooperation agreement includes standstill until 180 days after Ma-Weaver leaves board or 90 days before 2023 annual meeting.
- Company to explore and evaluate strategic options to maximize stockholder value.
- Ma-Weaver granted option to purchase 12,000 shares at $2.27 per share, vesting over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022023734/0001564590-22-023734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022023734/abio-8k_20220615.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer